A recent prospective phase II study (ECOG‐ACRIN E2211) demonstrated that MGMT deficiency was associated with a significant response to capecitabine and temozolomide (CAPTEM) in pancreatic neuroendocrine neoplasms (NENs); however, routine MGMT analysis in NENs was not recommended. The gene discussed is MGMT; the disease is pancreatic neuroendocrine neoplasm.